ACS Clinical Research Program rss


Modified FOLFIRINOX is superior to gemcitabine as adjuvant therapy for resected pancreatic cancer: The PRODIGE 24/CCTG PA6 Trial(0)

January 1, 2020

The study design and findings of the PRODIGE 24/CCTG PA6 Trial are outlined, which showed improved survival with modified FOLFIRINOX for resected pancreatic cancer patients.

Figure 1. Schema: ALCHEMIST CHEMO-IO

ALCHEMIST trial has potential to improve outcomes after lung cancer resection

The ALCHEMIST CHEMO-IO is a trial for patients with early-stage non-small cell lung cancer (NSCLC) with the potential to change the way patients with resected NSCLC are treated.


Could axillary reverse mapping be useful in reducing surgical comorbidities?

A summary of some of the research that evaluates the role of axillary reverse mapping in cancer patients.


Evolution in the management of desmoid tumors: Challenging the role of upfront surgical resection

Describes the traditional management of desmoid tumors as well as new approaches, including radiation therapy for locally aggressive tumors.


Putting the needle before the knife: Minimally invasive approaches to diagnostic lymph node biopsy in melanoma

Minimally invasive approaches to diagnostic lymph node biopsy in melanoma are recommended as a first step in value-based care for the patient.

More in this category

« Older Posts   


Bulletin of the American College of Surgeons
633 N. Saint Clair St.
Chicago, IL 60611


Download the Bulletin App

Apple Store
Get it on Google Play
Amazon store